Last updated on July 2019

An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS Intermediate or High-Risk Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib


Brief description of study

This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib.

The primary objective of the study is to evaluate the percentage of subjects with at least a 35% reduction of spleen volume and one of the secondary objectives is to evaluate the safety of fedratinib

Clinical Study Identifier: NCT03755518

Find a site near you

Start Over

Mayo Clinic Phoenix

Phoenix, AZ United States
  Connect »

Mayo Clinic - Jacksonville

Jacksonville, FL United States
  Connect »

St. Agnes - Medical Center

Baltimore, MD United States
  Connect »

North Carolina Women's Hospital

Chapel Hill, NC United States
  Connect »

UC Health Barrett Cancer Center

Cincinnati, OH United States
  Connect »

Avera Cancer Institute

Sioux Falls, SD United States
  Connect »

UT Health - San Antonio

San Antonio, TX United States
  Connect »